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Background: Several studies suggested an important role of the gut microbiota
in the pathophysiology of neurological disorders, implying that alteration of the gut
microbiota might serve as a treatment strategy. Fecal microbiota transplantation (FMT)
is currently the most effective gut microbiota intervention and an accepted treatment
for recurrent Clostridioides difficile infections. To evaluate indications of FMT for patients
with neurological disorders, we summarized the available literature on FMT. In addition,
we provide suggestions for future directions.
Methods: In July 2019, five main databases were searched for studies and case
descriptions on FMT in neurological disorders in humans or animal models. In addition,
the ClinicalTrials.gov website was consulted for registered planned and ongoing trials.
Results: Of 541 identified studies, 34 were included in the analysis. Clinical trials
with FMT have been performed in patients with autism spectrum disorder and showed
beneficial effects on neurological symptoms. For multiple sclerosis and Parkinson’s
disease, several animal studies suggested a positive effect of FMT, supported by
some human case reports. For epilepsy, Tourette syndrome, and diabetic neuropathy
some studies suggested a beneficial effect of FMT, but evidence was restricted to
case reports and limited numbers of animal studies. For stroke, Alzheimer’s disease
and Guillain-Barré syndrome only studies with animal models were identified. These
studies suggested a potential beneficial effect of healthy donor FMT. In contrast,
one study with an animal model for stroke showed increased mortality after FMT.
For Guillain-Barré only one study was identified. Whether positive findings from
animal studies can be confirmed in the treatment of human diseases awaits to be
seen. Several trials with FMT as treatment for the above mentioned neurological
disorders are planned or ongoing, as well as for amyotrophic lateral sclerosis.
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Conclusions: Preliminary literature suggests that FMT may be a promising treatment
option for several neurological disorders. However, available evidence is still scanty and
some contrasting results were observed. A limited number of studies in humans have
been performed or are ongoing, while for some disorders only animal experiments have
been conducted. Large double-blinded randomized controlled trials are needed to further
elucidate the effect of FMT in neurological disorders.
Keywords: fecal microbiota transplantation, nervous system diseases, gastrointestinal microbiome,
neurodegenerative, autoimmunity, gut-brain axis, Parkinson’s disease, autism spectrum disorder
Abbreviations: 3AIBA, 3-aminoisobutyric acid; 3-CST, three-chamber sociability
test; 5-HT, serotonin or 5-hydroxytryptamine; A, aged 18–20months oldmice; AB,
antibiotics; ABC, aberrant behavior checklist; AC, amoxicillin/clavulanate; AC Res,
amoxicilline/clavulanate-resistant; AC Sens, amoxicilline/clavulanate-sensitive;
AD, Alzheimer’s disease; AE, adverse event; Ampho-B, amphotericin B; APP, Aβ
precursor protein; APPPS1, co-expression of KM670/671NL Swedish mutation
of human amyloid precursor protein (APP) and L166P mutation of human
presenilin 1 (PS1) under control of the Thy-1 promoter with age-dependent Aβ
parenchymal accumulation and minimal vascular Aβ amyloid, restricted to the
pial vessels; APPPS1-21, amyloid precursor proteinSWE/ presenilin 1L166Pmouse
model of amyloid-β amyloidosis/Alzheimer’s disease that express familial AD–
linked APPSWE and PS1L166P transgenes driven by the neuron-specific Thy1
promoter; ASD, autism spectrum disorder; ASO, alpha-synuclein overexpression;
Aβ, amyloid beta; cAPPPS1, APPPS1 mice with conventional microbiota; CARS,
childhood autism rating scale; CD, cognitive dysfunction; CDi, control diet;
CD11b, a type of mouse antigen-specific antibodies; CDAI, Crohn’s disease activity
index; CFA, complete Freud’s adjuvant; CLDN1, claudin 1; cMCAO, permanent
occlusion of MCA distal of lenticulostriate arteries (cause small cortical lesions);
CNS, central nervous system; Conv-11168, mice are infected with C. jejuni from
enteric disease patient; Conv-260.94, mice are infected with C. jejuni from GBS
patient; Conv-TSB, mice are inoculated with tryptic soy broth; d, day(s); DA,
striatal dopamine; DSI, direct social interaction test; DSR, daily stool records; EAE,
experimental autoimmune encephalomyelitis; EDSS, expanded disability status
scale; fMCAO, transient occlusion of MCA by temporarily placing a filament in
the internal carotid artery; FMD, fasting mimicking diet; FMT, fecal microbiota
transplantation; FPD, Faith’s phylogenetic diversity; FST, forced swimming test;
GABA, gamma-aminobutyric acid; GBS, Guillain-Barré syndrome; GF, germ-free;
GI, gastrointestinal; GSI, gastrointestinal severity index; GSRS, gastrointestinal
symptom rating scale; HC, healthy control; HHC, human healthy household
control; HK, heat-killed; HN, high intensity noise; Hu, humanized; HWT, hang
wire test; i.c., ileocecocolic; i.p., intraperitoneal; IL, interleukin; KCNA1, Potassium
Voltage-Gated Channel Subfamily A Member 1; KDi, ketogenic diet; LN, low-
intensity noise; LPS, lipopolysaccharide; m, month(s); MB, marble burying test;
MCAO, middle cerebral artery occlusion; mNSS, modified neurological severity
score; MOG, myelin oligodendrocyte glycoprotein; MPTP, 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine; (SP)MS, (secondary progressive) multiple sclerosis;
MSFC, Modified Multiple Sclerosis Functional Composite; MWMT, morris water
maze test; MWT, mechanical withdrawal test; N, normal; NA, data not available;
ND, normally developing; NDS, neurological deficit score; Non-anh, spared nerve
injury without developing a anhedonia-like phenotype; NF, mice that were treated
with normal saline by intraperitoneal injection and fasting mimicking diet; non-
sign., non-significant; NS, normal saline; OFT, open-field testing; OLT, object
location test; ORT, novel object recognition test; OTU, operational taxonomic
unit; PAC-QOL, patient assessment of constipation–quality of life; PANDAS,
pediatric autoimmune neuropsychiatric disorders associated with streptococcal
infections syndrome; PANS, pediatric acute-onset neuropsychiatric syndrome;
PBS, phosphate-buffered solution; PBS/G,mice that were treated with 20% glycerol
in sterile phosphate-buffered solution; PCoA, principal coordinates analysis;
PD, Parkinson’s disease; PGI-III, parent global impressions-III; PGI-R, parent
global impressions-revised; phylog. div, phylogenetic diversity; PLS-DA, partial
least squares discrimination analysis; PPA, propionic acid; Qol, quality of life;
RR, relapsing-remitting; SAE, serious adverse event(s); SAMP8, senescence-
acceleratedmouse prone 8; SAMR-1, senescence-acceleratedmouse resistant 1; SC,
INTRODUCTION
The bidirectional communication between the gut and the
central nervous system, often referred to as the gut-brain axis,
has been a topic of great interest in the past decade. Several
studies suggest an important role of the gut microbiota in the
pathophysiology of neurological disorders. A different human
gut microbiota composition compared to healthy controls
has been reported for several neurological disorders, such as
Parkinson’s disease (Hasegawa et al., 2015; Keshavarzian et al.,
2015; Scheperjans et al., 2015; Unger et al., 2016), multiple
sclerosis (Miyake et al., 2015; Chen et al., 2016; Jangi et al.,
2016; Cosorich et al., 2017), autism spectrum disorder (Finegold
et al., 2002, 2010; De Angelis et al., 2013, 2015; Kang et al., 2013;
Ma et al., 2019), Alzheimer’s disease (Vogt et al., 2017; Zhuang
et al., 2018; Haran et al., 2019; Li B. et al., 2019; Liu et al.,
2019), neuromyelitis optica (Cree et al., 2016), Rett syndrome
(Strati et al., 2016), epilepsy (Xie et al., 2017; Peng et al., 2018;
Lindefeldt et al., 2019), amyotrophic lateral sclerosis (Fang et al.,
2016; Rowin et al., 2017; Mazzini et al., 2018), cerebral infarction
(Karlsson et al., 2012; Yin et al., 2015), spinal cord injury
(Gungor et al., 2016), and multiple system atrophy (Tan et al.,
2018). However, data on microbiota composition are frequently
inconsistent and numerous potential confounders are involved.
Interestingly, patients with these neurological disorders often
experience gastrointestinal symptoms (Poewe, 2008; Adams et al.,
2011; Postuma et al., 2012; McElhanon et al., 2014; Willison et al.,
2016), which could imply that the intestinal tract is involved
in disease pathophysiology. Onset, clinical characteristics and
progression of these neurological disorders may potentially be
modulated by gut microbiota interventions. Gut microbiota
interventions could also affect availability and pharmacokinetics
sodium citrate buffer (control for FMT); SCFA, short chain fatty acids; SD, Sprague
Dawley; SDI, stroke dysbiosis index; SDI-H, stroke patients with a high stroke
dysbiosis index; SDI-L, stroke patients with a low stroke dysbiosis index; SGHM,
Standardized Human Gut Microbiota; SNI, spared nerve injury; SPF, specific-
pathogen-free; SPT, Sucrose preference test; SRS, Social Responsiveness Scale;
STER, mice are handled sterile; SW, Swiss-Webster; T1D, type 1 diabetes mellitus;
TET, Transendoscopic enteral tubing; TFT, Tail-flick test; Th, T-helper cells, Thy1-
αSyn, alpha-synuclein-overexpression mouse model; TLR, toll-like receptor; TNF,
tumor necrosis factor; Treg, regulatory T cells; TS, Tourette syndrome; TSB, tryptic
soy broth; TST, tail suspension test; UPDRS, unified Parkinson’s disease rating
scale; USV, ultrasonic vocalizations test; VABS-II, Vineland Adaptive Behavior
Scale II; VAS, Visual analog scale; w, week(s); w., weighted; WT, wild-type; y,
year(s); y.o., year old; Y, young 8-12 weeks old mice; YGTSS, Yale Global Tic
Severity Scale; ZO-1, tight junction protein 1.
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of medication for neurological disorders, which may lead to an
increased efficacy and a different side effect profile. There are
multiple gut microbiota interventions, e.g., the administration of
antibiotics, probiotics, prebiotics, synbiotics, or fecal microbiota
transplantation (FMT). Antibiotic treatment has been reported
to change disease course in a few neurological disorders (Sandler
et al., 2000; Laake and Oeksengaard, 2002; Fasano et al., 2013;
Ghanizadeh and Berk, 2015; Angelucci et al., 2019; Lum et al.,
2019). Probiotics may improve disease symptoms, but results
are inconsistent (Parracho et al., 2010; Kaluzna-Czaplinska and
Blaszczyk, 2012; West et al., 2013; Partty et al., 2015; Jiang
et al., 2017; Shaaban et al., 2018; Gazerani, 2019; Kobayashi
et al., 2019a,b; Tamtaji et al., 2019). The most effective option
in modulation of the gut microbiota is FMT, which includes
administration of a solution of fecal matter from a donor into
the intestinal tract of a recipient. FMT is an efficacious treatment
for recurrent Clostridioides difficile infections (van Nood et al.,
2013; Kelly et al., 2016). It is currently under investigation for
several neurological disorders. Publications on FMT in humans
with and animal models of neurological disorders are discussed
in this narrative review.
METHODS
Data Sources and Search Strategy
In July 2019, a literature search on FMT in neurological
disorders was performed in five main databases, including
Pubmed, Embase, Web of Science, COCHRANE library and
Academic Search Premier database, using appropriate keywords
(Appendix 1). Meeting and congress abstracts were also
included. Furthermore, the reference lists of some recent reviews
were consulted to detect relevant additional publications. In
addition, the website ClinicalTrials.gov was searched (June 27th
2019) for ongoing or planned clinical trials with FMT in
neurological disorders. Further details of the search strategy are
provided in Appendix 1.
Study Selection
Eligibility was assessed by screening titles and abstracts. The
following inclusion criteria were applied: (1) in vivo studies or
case descriptions with FMT in humans or animal models; (2)
FMT with feces from healthy humans or animals transferred
to humans with, or animal models of, individual neurological
disorders; or FMT with feces from humans with, or animal
models of, individual neurological disorders transferred to
healthy humans or animals; (3) original research; (4) articles
in English.
Two exclusion criteria were applied: (1) Use of individual
bacteria, bacterial groups or bacterial metabolites instead of feces;




The initial search yielded 541 articles and abstracts. After
exclusion of articles or abstracts not meeting the abovementioned
criteria, 34 articles and abstracts remained. All included FMT
studies are reported in Tables 1–9. Figure 1 shows the most
important effects of FMT in humans and animals for neurological
disorders. An overview of planned and ongoing studies, found
on the website ClinicalTrials.gov, is provided in Appendix 2.
Abbreviations and terms are explained in Appendix 3.
Neurological Disorders With FMT Studies
in Both Patients and Animal Models
Autism Spectrum Disorder
Role of the gut microbiota in disease symptoms and
pathogenesis
Autism spectrum disorder (ASD) is a group of
neurodevelopmental disorders, characterized by altered
social communication and interaction as well as repetitive,
stereotyped behavior.
The exact etiology is unknown: a combination of genetic
and environmental risk factors, dysregulation of the immune
system, inflammation and also maternal factors is proposed
(Fattorusso et al., 2019). Increased systemic (Ashwood et al.,
2011) and neuroinflammation (Vargas et al., 2005; Li et al.,
2009) and even brain-specific autoantibodies (Vojdani et al.,
2002; Silva et al., 2004; Connolly et al., 2006; Cabanlit et al.,
2007; Wills et al., 2009), though not confirmed in another
study (Todd et al., 1988), have been observed in ASD patients.
Hyperserotoninemia in ASD patients may also contribute to the
etiology (Fattorusso et al., 2019).
ASD patients have a different gut microbiota composition
and different gut metabolomes (including neurotransmitters)
compared to healthy controls (Finegold et al., 2002, 2010;
De Angelis et al., 2013, 2015; Kang et al., 2013; Ma et al.,
2019). Relatively higher levels of the phylum Bacteroidetes,
which produces short-chain fatty acids (SCFA), are observed
in ASD subjects. Furthermore, decreased levels of the anti-
inflammatory genus Bifidobacterium or increased levels of the
genus Clostridium, which is known to produce potentially toxic
metabolites such as phenols and p-cresols, may play a role
in pathogenesis (Fattorusso et al., 2019). Altered production
of gut-microbial metabolites, such as p-cresol and SCFA, are
associated with ASD symptoms (MacFabe et al., 2007; Fattorusso
et al., 2019). An increased intestinal production of serotonin and
decreased cerebral serotonin synthesis in ASDmay also be caused
by alterations in the gut microbiota, but evidence is inconsistent
(Fattorusso et al., 2019). Data on α-diversity in gut microbiota of
ASD patients are also contrasting (Finegold et al., 2010; Williams
et al., 2011; De Angelis et al., 2013; Kang et al., 2013; Ma et al.,
2019). An altered gut microbiota composition may influence
the immune system, inflammation and metabolism and thereby
increase the risk for ASD (Park, 2003; Fattorusso et al., 2019).
Diet, which is known to shape the gut microbiota (David et al.,
2014), is also thought to modulate ASD behavior (Knivsberg
et al., 2002; Cermak et al., 2010; Whiteley et al., 2010; de Theije
et al., 2014; Fattorusso et al., 2019).
Gastrointestinal symptoms, such as abdominal pain,
constipation, diarrhea, and bloating, are more frequently
described in ASD patients than controls, with a corresponding
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FIGURE 1 | Potential effects of FMT in patients with neurological disorders and in animal models for neurological disorders. The figure includes studies in which
patients with a neurological disorder or animal models for a neurological disorder received FMT with feces from a healthy donor. Tourette syndrome was not included
as this contains only one case report. Blue areas include cognitive symptoms, yellow areas include motor and sensory symptoms or effects and orange areas include
other effects. The outer parts contain results from human studies and the inner parts from animal studies. Statements in bold are found by more than one study,
excluding case descriptions. N: the number of studies identified per neurological disorder, subdivided in human and animal studies. *based on case reports/series only
(very limited evidence). **inconsistent results.
odds ratio of 4.42 (McElhanon et al., 2014). Some studies found
an association between gastrointestinal symptoms and severity
of ASD symptoms (Adams et al., 2011; Wang L. W. et al., 2011;
Mazurek et al., 2013), but others could not reproduce these
findings (Kang et al., 2013; Son et al., 2015). ASD patients appear
to have a higher prevalence of IBD (Doshi-Velez et al., 2015)
and a higher number of pro-inflammatory immune cells in
the intestinal wall (Navarro et al., 2016), although intestinal
inflammatory markers, such as fecal calprotectin, appear normal
(Navarro et al., 2016). The gastrointestinal symptoms may
be caused by the presence of more pro-inflammatory gut
bacteria (Fattorusso et al., 2019), but other factors may also be
involved (Mayer et al., 2014). Studies have also reported altered
gastrointestinal motility and increased intestinal permeability in
ASD (D’Eufemia et al., 1996; Boukthir et al., 2010; de Magistris
et al., 2010), which may increase the risk of translocation of
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 4 March 2020 | Volume 10 | Article 98
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bacteria or neurotoxic peptides, such as lipopolysaccharide (LPS).
However, inconsistency is again observed (Navarro et al., 2016).
Another important finding that supports a role for the
gut microbiota is a temporary improvement of ASD and
gastrointestinal symptoms after 8 weeks of oral vancomycin
treatment (Sandler et al., 2000). Furthermore, several studies on
the effect of probiotics in ASD patients and ASD animal models
showed a positive effect on ASD symptoms (Parracho et al.,
2010; Kaluzna-Czaplinska and Blaszczyk, 2012; Hsiao et al., 2013;
West et al., 2013; Partty et al., 2015; Shaaban et al., 2018). This
included improvement of neurobehavioral symptoms, such as
anxiety or problems with concentration, and/or gastrointestinal
symptoms (Parracho et al., 2010; Kaluzna-Czaplinska and
Blaszczyk, 2012; Hsiao et al., 2013; West et al., 2013; Partty
et al., 2015; Shaaban et al., 2018). One human study reported
the absence of onset of Asperger syndrome in a group of
40 children of which the mothers during pregnancy or post-
partum and, in case there was no breastfeeding, the children
themselves had received probiotics (Lactobacillus rhamnosus
GG) for 6 months as opposed to 3 out of 35 children who
developed Asperger syndrome in the placebo group (Partty et al.,
2015).
In animal studies, germ-free male mice showed increased
social impairments compared to conventionally colonized mice,
which suggests an important role for gut microbiota in this
behavior (Desbonnet et al., 2014).
FMT studies in animal models (Table 1)
Sharon et al. (2019) performed FMT in germ-free wild-
type mice with feces from children with ASD or normally
developing children. The ASD group and their offspring had
ASD-like symptoms. Furthermore, brains of offspring displayed
alternative splicing of ASD-relevant genes. When gamma-
aminobutyric acid (GABA)A receptor agonists, reduced in
the ASD-group colon, were administered to an ASD mouse
model, ASD symptoms decreased. Another study (Aabed
et al., 2019) observed decreased cerebral oxidative stress
after FMT with feces from a normal hamster in an ASD
hamster model. This effect was stronger after administration of
Lactobacillus paracaseii.
FMT studies in patients (Table 1)
In an open-label clinical trial (Kang et al., 2017, 2019), 18
children with ASD and gastrointestinal symptoms received
daily FMT for 7–8 weeks by mixing standardized human gut
microbiota with a drink or via enema. Gastrointestinal and
behavioral ASD symptoms improved, which persisted until 2
years after treatment. FMT appeared safe, since most adverse
events were temporary and observed at start of vancomycin
pre-treatment (e.g., mild to moderate tantrums/aggression
and hyperactivity) and 5% suffered from nausea/vomiting.
Furthermore, there was a correlation between ASD symptoms
and gastrointestinal symptoms. However, this was an open-
label study without a placebo group in a heterogenous group
of 18 participants, in which 12 changed their medication,
diet, or nutritional supplements during the study. Furthermore,
there was no vancomycin-only group and no information
on adverse events in the long-term follow-up was provided
(Kang et al., 2017, 2019).
An abstract (Zhao et al., 2019) reporting an open-label,
randomized waitlist-controlled trial showed improvements of
ASD symptoms and changes in gastrointestinal symptoms
2 months after two FMTs in 24 ASD-children compared
to 24 control ASD-children. However, improvement of ASD
symptoms was temporary. Seven FMT-patients reported adverse
events, such as nausea, fever and allergy, but these were all
mild and transient. There was no placebo-group and there was
lack of information on α- and β-diversity of the gut microbiota,
pre-treatment and amount of donor feces (Zhao et al., 2019).
In a case series described in an abstract (Ward et al.,
2016), ASD symptoms did not change in a 21-year-old man,
but were improved in eight younger subjects. Regression of
symptoms often occurred, mostly after antibiotics post-FMT,
but often improved again after re-FMT. In another case series
(Urbonas and Cervinskiene, 2018) (abstract only), the authors
described that the parent global impression score (PGI-R) and
gastrointestinal symptoms improved after three FMTs in five
boys with ASD and mild gastrointestinal symptoms. However,
PGI-R pre-FMT scores were not shown and scores did not appear
to improve over time.
One placebo-controlled randomized clinical trial (RCT) with
CP101, a drug that contains a full community of gut bacteria, is
planned and two RCT, of which one is placebo-controlled, with
FMT in human ASD subjects are ongoing (Appendix 2).
Multiple Sclerosis
Role of the gut microbiota in disease symptoms and
pathogenesis
Multiple sclerosis (MS) is a demyelinating disorder of the
central nervous system (CNS). The pathophysiology of MS is
complex and has not been fully elucidated. Genetic, infectious
and environmental factors (e.g., Epstein-Barr virus infection,
smoking, and sunlight/vitamin D) play pivotal roles (Olsson
et al., 2017). The interplay between these factors appears to
lead to immune dysregulation, but a true autoimmune origin
of the disease remains elusive. Nevertheless, the relative efficacy
of therapies targeting inflammation supports a critical role of
the immune system, in particular T-cell mediated mechanisms.
This includes limiting leukocyte egress from secondary lymphoid
organs and their entry into the CNS (Dendrou et al., 2015;
Thompson et al., 2018). Peripheral activation of CD8+ T-cells
and CD4+ T-helper cells (Th) type 1 and 17 allows for these cells
to infiltrate the CNS and cause inflammation. This peripheral
activation is thought to be caused by a reduction of regulatory
T cells (Treg) and antigen presentation of brain antigens in
secondary lymphoid organs (Dendrou et al., 2015). Infiltrating
macrophages are also critical to CNS inflammation.
The gut microbiota influences and modulates the equilibrium
between pro- and anti-inflammatory T-cells in the gut-associated
lymphoid tissue (Rooks and Garrett, 2016; Yissachar et al.,
2017). Several studies have been performed which characterized
the gut microbiota profile of patients suffering from different
forms of MS. Similar subtle alterations in gut microbiota
composition were found throughout these studies via analyses



























TABLE 1 | FMT in autism spectrum disorder.

































































































































































































































































































TABLE 1 | Continued

























9 Unclear ASD symptoms:
unchanged in 21
y.o., improved in



























































































































































































































































































































































































































































































































































































































































































































































































of fecal samples (Miyake et al., 2015; Chen et al., 2016; Jangi
et al., 2016). One study found a similar perturbed microbiota
composition within duodenal mucosal biopsies (Cosorich et al.,
2017). Based on these studies, it could be hypothesized that MS
patients’ gut microbiota harbors less bacterial species that can
induce Treg cells, which may contribute to elevated peripheral
levels of Th1 and 17 (Jangi et al., 2016; Cekanaviciute et al.,
2017). It is hypothesized that subsequently elevated Th1 and
17 cause inflammation in the CNS and increased blood-brain
barrier permeability, leading in turn to exacerbation of the
inflammation of the CNS (Dendrou et al., 2015). Modulation of
the gut microbiota to induce more Treg cells could lead to less
activation of pathogenic T-cells (Berer et al., 2014). Interestingly,
gavage with a human gut-derived commensal strain Prevotella
histicola resulted in a decreased incidence of disease in a mouse
model of MS (Mangalam et al., 2017). Moreover, a decrease
in Th1 and 17 cell numbers and an increase in Treg cells
were found.
FMT studies in animal models (Table 2)
Experimental autoimmune encephalomyelitis (EAE) is an animal
model that mimics aspects of pathophysiology and symptoms
of MS (Goverman et al., 1993). The gut microbiota is required
to induce EAE, as germ-free mice did not develop spontaneous
EAE in a transgenic model (Berer et al., 2011). Two mouse EAE
studies used gavage to transplant MS patients’ or healthy human
controls’ microbiota. The transplanted MS microbiota resulted
in an increased EAE incidence, a more severe disease course
and a decrease in expression of anti-inflammatory cytokine IL-10
(Berer et al., 2017; Cekanaviciute et al., 2017). In general, these
findings seem to correlate with current interpretations of the
distinct immunological findings in MS-patients (Dendrou et al.,
2015).
FMT studies in patients (Table 2)
Currently, there are only two case reports/series on effects
of FMT on MS symptoms and disease progression (Borody
et al., 2011; Makkawi et al., 2018). Both claim sustained
beneficial effects following FMT. One secondary progressive
MS patient was treated with a single FMT for concomitant
recurrent Clostridioides difficile infections. The FMT resolved
the recurrent C. difficile infections and was suggested to
prevent MS disease progression for over 10 years (Makkawi
et al., 2018). In the case-series amelioration of MS symptoms
following repeated FMTs was observed in three patients
(Borody et al., 2011).
ClinicalTrials.gov lists one ongoing RCT, one ongoing
non-randomized trial, and one planned prospective case-only
observational study in which MS patients receive FMT as an
experimental treatment (Appendix 2).
Parkinson’s Disease
Role of the gut microbiota in disease symptoms and
pathogenesis
Parkinson’s disease (PD) is a progressive neurodegenerative
disorder, characterized by neuron degeneration in the CNS,
enteric nervous system and peripheral autonomic nervous



























TABLE 2 | FMT in multiple sclerosis.
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system, and by the presence of Lewy bodies and Lewy
neurites in affected neurons (Pakkenberg et al., 1991). The
etiology and pathogenesis of PD is still largely unknown
and possibly heterogeneous. Both genetic and environmental
factors might play a role, at least in some forms of the
disease. The gut-brain axis in PD has been intensively
studied. Gastrointestinal symptoms (including obstipation
and delayed transit) are frequently observed in patients
with PD. In some cases they precede the onset of motor
symptoms and represent the first clinical manifestation of
PD (Poewe, 2008; Postuma et al., 2012).
An important factor in the etiology of PD is the aggregation of
the protein alpha-synuclein (αSyn), a major component of Lewy
bodies (Spillantini et al., 1997). Several studies demonstrated
that the enteric nervous system and vagus nerve are affected in
an early, and even in the prodromal, phase of disease (Braak
et al., 2003; Kuo et al., 2010; Hallett et al., 2012; Shannon
et al., 2012; Stokholm et al., 2016). It has been suggested that
the disease may start in the gut, with a neurotropic substance
with prion-like properties, possibly misfolded αSyn, that is
transported from the gastrointestinal tract to the CNS (Liautard,
1991; Braak et al., 2003). Mice studies indeed confirmed that
αSyn forms could be transported to the brain and pass the
blood-brain barrier (Pan-Montojo et al., 2010; Ulusoy et al.,
2013; Holmqvist et al., 2014; Kim et al., 2019). Moreover,
aggregation of αSyn in the brain, and possibly the gut, of
PD patients could be a consequence of inflammation-induced
oxidative stress (Shults, 2006; Keshavarzian et al., 2015). It is
indeed observed that PD patients have increased expression of
pro-inflammatory cytokines and glial markers in the colonic
biopsies compared to healthy controls (Devos et al., 2013). PD
patients also appear to have increased intestinal permeability
(Forsyth et al., 2011) and small intestine bacterial overgrowth
(Gabrielli et al., 2011; Fasano et al., 2013; Tan et al., 2014). The
latter is associated with more motor fluctuations when using
levodopa, which improves after antibiotics (Fasano et al., 2013).
Furthermore, several studies indicate that the gut microbiota
composition and the metabolome in PD patients are different
from healthy individuals (Hasegawa et al., 2015; Keshavarzian
et al., 2015; Scheperjans et al., 2015; Unger et al., 2016).
Overall, more pro-inflammatory gut bacteria, such as LPS-
producing Proteobacteria, and less anti-inflammatory butyrate-
producing gut bacteria are found in PD patients (Keshavarzian
et al., 2015). Scheperjans et al. (2015) found that the relative
abundance of the family Enterobacteriaceae in PD patients is
positively associated with postural instability and gait difficulty.
Two other important studies suggested that gut bacterial
tyrosine decarboxylases can metabolize levodopa to dopamine
without being susceptible for aromatic amino acid decarboxylase
inhibitors, such as carbidopa. Increased presence of gut bacterial
tyrosine decarboxylases may thereby cause response fluctuations
in levodopa/carbidopa-treated PD patients, as dopamine cannot
cross the blood-brain barrier (Maini Rekdal et al., 2019; van
Kessel et al., 2019). Furthermore, probiotics may improve PD
symptoms, but this includesmainly improvement of constipation
(Gazerani, 2019).
FMT studies in animal models (Table 3)
A recent study (Sampson et al., 2016) demonstrated that the
presence of gut microbiota is necessary for the development
of PD characteristics in alpha-synuclein-overexpressing
(ASO) mice. Germ-free ASO mice showed less motor
symptoms, constipation, alpha-synucleinopathy, and microglia
activation compared to specific-pathogen-free ASO mice, while
colonization with specific-pathogen-free microbiota led to an
increase of symptoms. When ASO mice received feces from
PD patients, motor symptoms increased compared to mice that
received healthy human feces (Sampson et al., 2016). Another
study (Sun et al., 2018) showed that a PD mouse model had
improved motor function, increased striatal neurotransmitters,
and decreased neuroinflammation after receiving feces from
healthy mice. Healthy mice that received feces from PD
mice had deteriorated motor function and decreased striatal
neurotransmitters compared to controls. Zhou et al. (2019)
observed less motor function decline and loss of dopaminergic
neurons in the substantia nigra in PDmice that received a fasting
mimicking diet (FMD) compared to ad-libitum-fed PD mice.
Furthermore, they observed a higher striatal dopamine and
serotonin concentration in PD mice that had received feces from
FMD-fed control mice compared to phosphate-buffered solution
(PBS)-gavaged or ad-libitummicrobiota-gavaged PD mice.
FMT studies in patients (Table 3)
There is only one case report (Huang H. et al., 2019)
describing a PD patient that received FMT in whom temporary
improvement of leg tremors and other PD symptoms was
observed 1 week after three FMTs. Unfortunately, leg tremors
recurred 2 months post-FMT and other PD symptoms had
also returned to baseline levels 1 month later. On the other
hand, constipation had also improved and this improvement
lasted until the end of follow-up 3 months post-FMT. No
further studies on FMT in PD were identified, except for one
communication in a divulgative magazine in which improvement
of PD symptoms after FMT was mentioned without further
details (Ananthaswamy, 2011).
On ClinicalTrials.gov, one RCT and one non-randomized
trial with FMT in PD patients are registered as ongoing
trials, and one placebo-controlled RCT with PRIM-DJ2727,
an orally administered lyophilized fecal microbiota product, is
planned (Appendix 2).
Epilepsy
Role of the gut microbiota in disease symptoms and
pathogenesis
In epilepsy, both genetic and environmental factors are thought
to be involved in individual predisposition, but exact etiology of
most cases remains unknown. A link between the gut microbiota
and the pathophysiology of epilepsy has been proposed by
some studies.
A difference in gut microbiota profiles between patients with
different types of therapy refractory epilepsy and healthy controls
was found in several studies. All these studies reported increased
abundance of the phyla Firmicutes relative to Bacteroidetes in
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subjects with refractory epilepsy (Xie et al., 2017; Peng et al.,
2018; Lindefeldt et al., 2019). Some bacteria of the phylum
Firmicutes may alter neurotransmitter levels (Peng et al., 2018).
Further microbiota analysis outcomes differed considerably
between these studies, including α-diversity measures (Xie et al.,
2017; Peng et al., 2018; Lindefeldt et al., 2019). One study
(Peng et al., 2018) found an increased Firmicutes/Bacteroidetes
ratio and α-diversity in drug-resistant patients compared to
drug-sensitive patients, with the latter being similar to healthy
controls. Importantly, α-diversity was probably increased due
to the abnormal increased abundance of rare bacteria. On
genus level, several differences were also found. Based on
these results, one could hypothesize a role for bacteria in
the effectivity of medication for epilepsy, but no causal
statements can be made (Peng et al., 2018). Interestingly,
zonisamide, an anticonvulsant drug, is metabolized by gut
bacteria (Kitamura et al., 1997). Furthermore, an increase in
Bifidobacteria and Lactobacillus was correlated with four or
less seizures per year (Peng et al., 2018). Another important
finding in patients with epilepsy is that a ketogenic diet reduces
the number of seizures and that a ketogenic diet is associated
with an altered gut microbiota composition and function
(Dahlin and Prast-Nielsen, 2019).
Sewal et al. (2017) found increased seizure susceptibility
after intraperitoneal administration of LPS in rats, which was
accompanied by increased blood-brain barrier permeability
and increased levels of pro-inflammatory cytokines in
the brain. Furthermore, contrasting results on whether
antibiotic treatment provides protective or inducing
effects on seizures are observed in animal and human
studies (Lum et al., 2019). Importantly, potential direct
neurotoxic effects of the antibiotics themselves or pro-
epileptogenic effects of the underlying disease (e.g., infection)
that is treated might rather be involved. Furthermore,
some studies found a positive effect of probiotics in
epilepsy (Gomez-Eguilaz et al., 2018; Yeom et al., 2019).
FMT studies in animal models (Table 4)
Medel-Matus et al. (2018) found that transfer of feces from
a stressed rat donor increased progression and duration of
kindled seizures (i.e., rearing, with or without falling) in sham-
stressed rats. The pro-epileptic effects were counteracted in
stressed recipients of donor feces from sham-stressed rats.
Another study (Olson et al., 2018) observed that a germ-
free temporal lobe epilepsy mouse model did not show
ketogenic diet-mediated seizure protection. They also observed
that the seizure threshold in specific-pathogen-free mice
increased after transplantation with ketogenic diet microbiota or
long-term administration of species Akkermansia muciniphila,
Parabacteroides merdae, and P. distasonis (associated with a
ketogenic diet).
FMT studies in patients (Table 4)
There is one case report (He et al., 2017) of a patient with
generalized epilepsy and Crohn’s disease that received three
FMTs. Before FMTs, she experienced frequent seizures when not
using sodium valproate treatment, and after FMTs, the patient
was seizure-free without antiepileptic drugs for 20 months.
Furthermore, the Crohn’s disease activity index improved (He
et al., 2017).
One registered interventional study with a single
group assignment is ongoing with FMT in patients with
epilepsy (Appendix 2).
(Diabetic) Neuropathic Pain
Role of the gut microbiota in disease symptoms and
pathogenesis
Neuropathic pain is pain that is caused by damage (e.g.,
nerve trauma or chemotherapeutic damage) or diseases (e.g.,
diabetes mellitus) of the peripheral or central somatosensory
nervous system. It is characterized by abnormal sensations or
pain following normally non-painful stimulation (Guo et al.,
2019). A potential complication of diabetes mellitus is peripheral
neuropathy with accompanying neuropathic pain and peripheral
neuropathy is positively associated with insulin resistance (Han
et al., 2015). Interestingly, patients with diabetes mellitus
have a different gut microbiota composition and function
compared to controls (Qin et al., 2012; Karlsson et al., 2013;
Jamshidi et al., 2019). FMT may alter insulin resistance and
thereby neuropathic pain. An increase in insulin resistance
was observed in germ-free wild-type mice after FMT with
feces from conventionally raised mice (Backhed et al., 2004).
In humans, FMT with feces from lean donors in subjects
with metabolic syndrome led to increased insulin sensitivity
(Vrieze et al., 2012).
The gut microbiota may also regulate pain by directly
modulating neuronal excitability of dorsal root ganglia or
indirectly by regulating neuroinflammation in the peripheral and
central nervous system (Guo et al., 2019). Microbiota depletion
by antibiotics or the complete absence of gut microbiota in
mice had a protective effect on pain in oxaliplatin-induced
peripheral neuropathy, accompanied by decreased infiltration
of macrophages and cytokines in the dorsal root ganglia.
The effect could be reversed by gut microbiota restoration
and this suggests an influence of the gut microbiota on
neuropathic pain (Shen et al., 2017). Another study demonstrated
a positive effect of probiotics in vitro on paclitaxel-induced
neuropathic pain features (Castelli et al., 2018). However,
when probiotics L. reuteri LR06 or Bifidobacterium BL5b were
administered to rats with chronic constriction injury-induced
neuropathic pain, no effect on pain sensation was observed
(Huang J. et al., 2019).
FMT studies in animal models (Table 5)
One study (Yang C. et al., 2019) observed an increased
pain-like phenotype in antibiotic-treated mice. Furthermore,
mice that received antibiotics and FMT with feces from a
neuropathic pain rat model with anhedonia-like phenotype
developed more pain-symptoms compared to antibiotic- and
PBS-treated mice. Mice that received antibiotics and non-
anhedonia microbiota showed less pain-symptoms compared
to PBS-treated mice, comparable to mice receiving feces from
sham-operated rats.
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TABLE 5 | FMT in (diabetic) neuropathic pain.
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FMT studies in patients (Table 5)
In a case report, a woman with poorly regulated type 2
diabetes mellitus and diabetic neuropathy experienced
improvement of limb pain and paresthesia after two FMTs.
Visual analog scale (VAS) pain score decreased. There
was improvement of motor conduction velocity in the
tibial nerve without improvement of sensory dysfunction
on electromyogram. Furthermore, fasting blood glucose
levels decreased and stabilized, and HbA1c decreased from
7.5 to 6.3. However, length of follow-up was unclear and
therefore it is unknown how long the improvements lasted
(Cai et al., 2018).
Tourette Syndrome
Role of the gut microbiota in disease symptoms and
pathogenesis
Tourette syndrome (TS) is a neurodevelopmental disorder
characterized by the presence of motor and phonic tics
with onset during childhood. It is considered to be caused
by an interplay between genetic, environmental and social
factors. Reports on an association of the gut microbiota
with TS or tic disorders in general are scarce. Liao et al.
(2019) observed a decrease of tic-like behaviors in a rat
model after administration of Lactobacillus plantarum PS128
which coincided with improved dopamine metabolism and
norepinephrine levels in the striatum and prefrontal cortex. A
study of 30 patients with pediatric acute-onset neuropsychiatric
syndrome (PANS) and pediatric autoimmune neuropsychiatric
disorders associated with streptococcal infections syndrome
(PANDAS), in which tic disorders may appear following a
streptococcal infection, revealed a different gut microbiota
composition compared to healthy controls. In addition, a
decrease in pathways involved in brain function and an increase
of some pathways involved in modulation of the antibody
response to intestinal inflammation were observed in younger
PANS/PANDAS patients, although the sample size was small
(Quagliariello et al., 2018). Another study (Snider et al.,
2005) found that penicillin plus azithromycin prophylaxis was
effective in decreasing streptococcal infections and the associated
neuropsychiatric disorders, including tic disorders, in PANDAS
patients. However, the role of the gut microbiota is unclear in
this case, as the improvement of the neuropsychiatric symptoms
could also be related simply to the concomitant suppression of
streptococcal infections. Moreover, the sample size was small and
the applied methodology was questionable (Budman et al., 2005).
In an open-label clinical trial, described in an abstract (Ding
et al., 2019), a transient decrease of tic severity was observed in
11 males with TS after treatment with three administrations of a
mixed bacterial community.
FMT studies in animal models
No animal studies on FMT and TS were identified.
FMT studies in patients (Table 6)
Zhao H. et al. (2017) described a case report of a child
with TS that had decreased tic severity at the follow-
up moment 8 weeks after FMT. The parents reported
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that they had observed disappearance of involuntary
phonation, a decrease in involuntary shrugging and improved
attention in the 8 weeks after FMT. Further follow-up was
not described.
Neurological Disorders With FMT Studies
Only in Animal Models
Stroke
Role of the gut microbiota in disease symptoms and
pathogenesis
In some studies, patients with stroke appeared to have an
altered gut microbiota composition compared to healthy controls
(Karlsson et al., 2012; Yin et al., 2015), although some other
studies reported that no change occurred or that change was
only temporary (Koren et al., 2011; Swidsinski et al., 2012).
However, these results may be confounded by factors, such
as age, type 2 diabetes mellitus or obesity, which are risk
factors for stroke that are associated with a different gut
microbiota composition (Qin et al., 2012; Karlsson et al.,
2013; Torres-Fuentes et al., 2017; An et al., 2018). For α-
diversity, studies are also contradictory (Yin et al., 2015;
Li N. et al., 2019). Furthermore, decreased neuronal injury
and improved cognitive performance was observed in diabetic
mice with bilateral common carotid arteries occlusion after
receiving Clostridium butyricum suspension intragastrically
(Sun et al., 2016).
Studies on the role of the gut microbiota in stroke are
frequently contradictory. It has been hypothesized that the
gut microbiota influences the severity of ischemic brain injury
following stroke. After stroke, reduced intestinal motility
combined with reduced α-diversity of bacterial species,
bacterial overgrowth and impaired intestinal barrier may
lead to formation of proinflammatory immune cells in the
gut-associated lymphoid tissue and subsequent infiltration
of the brain with increased infarct volume (Singh et al.,
2016). Possibly, the translocation of gut bacteria and their
metabolites is also involved (Caso et al., 2009; Chen et al.,
2019). However, gut microbiota depletion with bacterial
outgrowth of certain taxa and reduced α-diversity may
also have a protective effect on ischemic brain injury by
suppression of trafficking of effector T cells from gut to brain
(Benakis et al., 2016). The immune function appears to be
reduced after stroke, with impairment of the gut-associated
lymphoid tissue (Meisel et al., 2005; Schulte-Herbruggen et al.,
2009). Furthermore, the reduced intestinal motility in stroke
patients is reflected by the increased frequency of constipation
(Camara-Lemarroy et al., 2014).
Another role of the gut microbiota may be hypothesized
in the development of atherosclerosis and subsequent stroke.
Several studies in animal models and humans suggest that
the gut microbiota influences the formation of atherosclerotic
plaques (Stepankova et al., 2010; Koren et al., 2011; Wang Z.
et al., 2011; Gregory et al., 2015; Zhu et al., 2016). Symptomatic
atherosclerosis in humans is indeed associated with a different
gut microbiota composition and functional capacity (Karlsson
et al., 2012). Production of trimethylamine-N-oxide by the
gut microbiota may be associated with cardiovascular events,
including stroke (Nam et al., 2019; Yang S. et al., 2019), whereas
others studies suggest a protective effect (Yin et al., 2015; Collins
et al., 2016; Arduini et al., 2019). Nevertheless, atherosclerosis is
not the only determinant of stroke.
FMT studies in animal models (Table 7)
Winek et al. (2016) found similar infarct volumes but increased
mortality in temporarily antibiotic-treated mice after stroke
induction compared to stroke mice without antibiotics or
continuous antibiotics and sham-operated antibiotic-treated
mice. Temporarily antibiotic-treated mice also developed severe
colitis. When these mice received gavage with specific-pathogen-
free microbiota before stroke-induction, a similar mortality and
infarct volume was observed, but sample size was low. However,
colitis was prevented. This means colitis could not have caused
the increased mortality in the FMT-group. Antibiotics may have
played a role as mortality in the FMT-group was similar to
the antibiotic treated-stroke group (Winek et al., 2016). Two
other studies found more functional impairment, larger cerebral
infarct volume, and increased intestinal, systemic and cerebral
inflammation in (pseudo-)GF stroke mice that had received
dysbiotic post-stroke mouse or human microbiota compared
to mice receiving normal microbiota (Singh et al., 2016; Xia
et al., 2019). In addition, gavage with normal microbiota led to
reduced infarct volumes (Singh et al., 2016). In contrast, Benakis
et al. (2016) found a protective effect of microbiota depletion by
antibiotics on infarct volume. Reduced ischemic brain injury and
sensorimotor deficits were observed in amoxicillin/clavulanic
acid (AC)-sensitive mice treated with AC compared to AC-
resistant mice. AC-treated mice that had received AC-sensitive
microbiota revealed a decreased infarct volume compared to
mice receiving AC-resistant microbiota.
Another study found that gut microbiota in young mice
is altered after experimental stroke and resembles that of
uninjured aged mice. They found improved performance in
several behavioral tests, decreased mortality and infarct size
and decreased pro-inflammatory cytokines after FMT with
young microbiota compared to those receiving aged microbiota
(Spychala et al., 2018).
Alzheimer’s Disease
Role of the gut microbiota in disease symptoms and
pathogenesis
Alzheimer’s disease (AD) is a neurodegenerative disease with a
progressive decline in cognitive function and loss of neurons
and synapses. A combination of genetic and environmental
factors is thought to be involved in the etiology (Angelucci
et al., 2019). Pathology is characterized by intraneuronal deposits
of neurofibrillary tangles and extracellular accumulations of
abnormally folded amyloid beta (Aβ) proteins. Aβ proteins are
thought to be pro-inflammatory neurotoxic proteins (Calsolaro
and Edison, 2016). However, the hypothesis that Aβ proteins
depositions lead to synaptic dysfunction and subsequently
symptoms has been questioned (Selkoe and Hardy, 2016). It is
unclear whether Aβ protein deposition may be the cause or result
of AD. There could be a vicious cycle between Aβ accumulation
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leading to microglia activation andmicroglia dysfunction leading
to Aβ accumulation (Cai et al., 2014). Neuroinflammation is
thought to play a key role in AD (Calsolaro and Edison, 2016).
In recent years, numerous publications on the relation
between AD and the gut microbiota have become available. AD
patients have a different gut microbiota composition compared
to healthy controls or elderly without dementia (Vogt et al., 2017;
Zhuang et al., 2018; Haran et al., 2019; Li B. et al., 2019; Liu
et al., 2019), but α-diversity measures show contrasting results
(Vogt et al., 2017; Li B. et al., 2019; Liu et al., 2019; Saji et al.,
2019). Hypotheses on the role of the gutmicrobiota include direct
actions of bacteria, indirect actions or aging-related processes
(Angelucci et al., 2019).
Studies have demonstrated the presence of microorganisms
in brains of both AD patients and healthy controls. However,
increased LPS levels (Zhan et al., 2016; Zhao Y. et al., 2017) and
an increased presence of several bacteria and fungi, including
some gut commensals, were observed in brains of AD patients
compared to controls (Mawanda and Wallace, 2013; Pisa et al.,
2017; Alonso et al., 2018; Dominy et al., 2019). The presence of
bacterial LPS or endotoxin-mediated inflammation contributes
to amyloid neurotoxicity (Zhao et al., 2015). A study found
that LPS in the brain colocalizes with AD-related Aβ proteins
in amyloid plaques (Zhan et al., 2016). Interestingly, the LPS-
and microorganism-detecting receptor CD14, important in the
neutralization of invading microorganisms, is also stimulated
by Aβ fibrils (Zhao et al., 2015). Furthermore, feces of patients
with brain amyloidosis and cognitive impairment contain
more pro-inflammatory gut bacteria and blood more pro-
inflammatory cytokines compared to patients with cognitive
impairment without amyloidosis or controls. In addition,
less anti-inflammatory bacteria and cytokines are observed
(Cattaneo et al., 2017). Interestingly, certain bacteria can produce
extracellular bacterial amyloids known as “curli fibers,” a main
component of biofilms for these bacteria. Some bacteria that
produce these curli fibers are recognized by the same Toll-like
receptor as the Aβ42 peptide that accumulates in AD (Zhao et al.,
2015; Tursi and Tükel, 2018). Increased levels of E. coli, a curli
fiber producer, were indeed found in AD brains compared to
controls (Zhan et al., 2016). However, it is unknown whether
bacterial amyloids co-localize with the amyloid deposits or other
insoluble lesions that are observed in AD (Zhao et al., 2015;
Tursi and Tükel, 2018). Bacteria may also contribute to AD
by production of neurotransmitters and altering proteins and
receptors involved in synaptic plasticity (Barrett et al., 2012;
Maqsood and Stone, 2016).
Apart from the direct action of bacteria, it is suggested that
certain gut microbiota alterations may stimulate inflammatory
pathways and thereby neuroinflammation (Marques et al.,
2016). Some researchers hypothesized that Aβ depositions are
part of an innate immune response that normally protects
against microbial infections in the brain (Moir et al., 2018).
A decrease of Aβ accumulation and microglia activation after
antibiotic treatment has indeed been observed. Conversely, other
studies suggested that microbiota depletion may negatively affect
cognitive function and microglia and synaptic function in mice
and contrasting results were also observed in humans (Laake
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and Oeksengaard, 2002; Angelucci et al., 2019). Furthermore, a
positive effect of probiotics on cognitive function was observed
in animal models and AD patients or adults with mild cognitive
impairment (Davari et al., 2013; Jiang et al., 2017; Kobayashi et al.,
2017, 2019a; Rezaei Asl et al., 2019; Tamtaji et al., 2019), whereas
one study reported no to little effect (Kobayashi et al., 2019b).
Erny et al. (2015) observed defects of microglia in germ-free
mice leading to impaired innate immune responses. This is in line
with the hygiene hypothesis, that proposes that AD patients have
reduced microbial diversity due to environmental sanitation and
therefore an impaired response to pathogens, with an important
role for T cells, in particular Treg cells (Larbi et al., 2009; Browne
et al., 2013; Dansokho et al., 2016; Hu et al., 2016). Furthermore,
with increasing age, an increase in proinflammatory cytokines
and decrease in anti-inflammatory gut bacteria is observed (Biagi
et al., 2010). This inflamm-aging may also be associated with
cognitive decline (Franceschi et al., 2000).
FMT studies in animal models (Table 8)
Zhan et al. (2018) observed that wild-type mice showed
decreased cognitive function after broad-spectrum antibiotic
treatment. Subsequently, spatial learning and memory improved
after receiving feces from senescence-resistant mice (similar to
control) compared to mice receiving feces from senescence-
prone mice (similar to antibiotics plus vehicle). Using diabetic
mice with and without cognitive deterioration gave a similar
result (Yu et al., 2019), although this is not a mouse model
of AD but cognitive deterioration secondary to diabetes. These
two studies suggest that antibiotics decrease cognitive function
in mice, which may be reversed by FMT. In contrast, two
studies (Harach et al., 2017; Dodiya et al., 2019) observed
reduced Aβ-pathology and neuroinflammation in male mice
(not in female mice) when the gut microbiota was depleted.
When an AB-treated AD mouse model received FMT with feces
from age- and sex-matched AD mice without antibiotics, the
positive effect of antibiotics was partially reversed (Dodiya et al.,
2019). In a germ-free AD mouse model, FMT with conventional
microbiota or conventional AD microbiota caused an increase
of pathology, with the latter showing a stronger effect (Harach
et al., 2017). Another study with germ-free wild-type mice found
a deterioration of cognitive function with lower fecal metabolites
related to the nervous system, such as GABA, in aged, and not
young, mice that received AD feces compared to healthy control
feces (Fujii et al., 2019).
Cui et al. (2018) found that the chronic noise exposure-
associated increased risk for AD in mice may be mediated
by the gut microbiota, and that chronic noise causes age-
related neurochemical and inflammatory dysregulation.
Gavage with feces from high-intensity noise AD mice to
age-matched recipient AD mice led to increased cerebral Aβ
and affected intestinal and blood-brain barrier compared to
control-microbiota recipients.
FMT studies in patients
No published FMT-studies in humans with AD were found, but
ClinicalTrials.gov showed an ongoing RCT with FMT in patients
with AD.
Guillain-Barré Syndrome
Role of the gut microbiota in disease symptoms and
pathogenesis
Guillain-Barré syndrome (GBS) is a paralytic neuropathy,
assumed to be caused by an auto-immune response after
infection or other immune stimulation, predominantly
preceded by gastrointestinal infection with Campylobacter
jejuni. The disease is frequently characterized by rapidly
progressing bilateral weakness. This may be accompanied
by additional neurologic or autonomic symptoms. Symptom
severity varies among different patients. Eventually, most
patients improve, but permanent disability can occur
(Willison et al., 2016).
Several studies reported an association between C.
jejuni colonization/infection and the gut microbiota. C.
jejuni colonization may be inhibited by gut microbiota-
mediated colonization resistance (Brooks and Mansfield,
2017). However, several studies suggest that C. jejuni may
overcome this colonization resistance in several ways, such
as increasing acetinogenesis gene expression, which leads
to the conversion of pyruvate to acetate (Ducarmon et al.,
2019). Inoculation of mice with C. jejuni strains from GBS
patients causes less colitis but more autoantibodies with
increased peripheral nerve lesions compared to inoculation
with C. jejuni strains from colitis patients (Malik et al.,
2014; St Charles et al., 2017). This is exacerbated after
antibiotic treatment (St Charles et al., 2017; Brooks et al.,
2019). The production of cross-reactive anti-ganglioside
antibodies during C. jejuni infection due to molecular mimicry
between bacterial LPS of GBS-associated C. jejuni strains
and peripheral nerve gangliosides have been considered
as one of the factors associated with the development of
GBS (Jacobs et al., 1997; Yuki, 1997; Ang et al., 2002). This
molecular mimicry is more frequently observed in GBS-
associated C. jejuni strains compared to colitis-associated C.
jejuni strains.
Antibiotic-treated and gnotobiotic mice display increased
colonization and gastrointestinal inflammation after C. jejuni
inoculation (Chang and Miller, 2006; Stahl et al., 2014;
O’Loughlin et al., 2015), with a potential protective role for
Enterococcus faecalis (O’Loughlin et al., 2015). Furthermore, a
considerably decreased C. jejuni clearance time is observed in
mice that receive antibiotics and gavage with murine microbiota
compared to human microbiota-receiving mice and gnotobiotic
mice, that showed a more pro-inflammatory immune response
(Bereswill et al., 2011).
Moreover, probiotics were successful at reducingC. jejuni load
in poultry (Morishita et al., 1997; Willis and Reid, 2008). This
was also confirmed by one mouse study (Wagner et al., 2009) and
one study showed that a probiotic inhibited C. jejuni invasion of
human intestinal epithelial cells (Wine et al., 2009).
FMT studies in animal models (Table 9)
Brooks et al. (2017) observed increased colonization, Th-2
responses (independent of inoculation status) and autoimmune
responses after C. jejuni injection in a human microbiota-treated
mouse group compared to a conventional mouse microbiota



























TABLE 8 | FMT in Alzheimer’s disease.
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TABLE 8 | Continued
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group. However, this should be interpreted with caution as C.
jejuni strains may have been adapted to the human microbiota,
while human and animal gut microbiota differ. This study
suggests that a particular gut microbiota composition may
enhance susceptibility to GBS after C. jejuni infection.
Ongoing Studies in Other Neurological
Disorders
Although no FMT-studies are available yet for amyotrophic
lateral sclerosis, one placebo-controlled RCT with FMT in
human amyotrophic lateral sclerosis patients is registered
on ClinicalTrials.gov.
DISCUSSION
Neurological disorders are complex, often involving cognitive,
motor and systemic aspects. A combination of genetic and
environmental factors is mostly thought to be involved in the
pathogenesis, with the gut microbiota being one potential factor.
Gut microbiota manipulation by FMT may influence symptoms
or progression of neurological disorders by gut microbiota-
mediated immunological, endocrine, metabolic and/or neural
pathways. Gut microbiota-produced metabolites and cytokines
may influence the level of intestinal and systemic inflammation
and may alter intestinal barrier function. The vagus nerve
provides a direct neural connection between the gut and the brain
and may play an important role. Furthermore, gut microbiota
interventions may influence the availability and efficacy of
medication by directly or indirectly interacting with the
processing of drugs or by modulation of the immune response.
Gut microbiota manipulation by FMT could be a promising
treatment approach for several neurological disorders, but the
evidence is limited. The neurological disorder with the most
evidence on efficacy of a healthy donor FMT is ASD. Various
articles, including clinical trials in humans, suggest that FMT
leads to decreased symptom severity. FMT may alter production
of gut microbial metabolites, such as serotonin, SCFA or GABA
receptor agonists, whereas a reduction of pro-inflammatory gut
bacteria may decrease neuro- and systemic inflammation and
cerebral oxidative stress. However, the reliability of conclusions
in humans might be undermined by the lack of a blind design,
as a placebo-effect may play an important role. More and larger
double-blind controlled studies are needed. For PD, MS, AD
and stroke, several animal studies suggest a positive effect of
FMT, supported by some case reports in humans. The potential
beneficial effects of FMT for patients with PD could be mediated
through a decreased α-syn accumulation in the intestinal wall
and subsequently in the brain, by reduced inflammation-induced
oxidative stress. Beneficial effects on Parkinson symptoms could
be further strengthened by an increased availability and efficacy
of levodopa following FMT with feces from donors with less
bacterial tyrosine decarboxylases in their feces (Maini Rekdal
et al., 2019; van Kessel et al., 2019). Remarkably, one mouse
study showed that administration of PD feces is enough to induce
PD symptoms (Sun et al., 2018), whereas another study showed
that genetic abnormalities in addition to a certain microbiota
composition is necessary to induce PD symptoms (Sampson
et al., 2016). In MS patients, an increase in Treg cells after
FMT may attenuate auto-immunity with demyelination and
possibly disease progression. Furthermore, FMT with feces from
young healthy donors may decrease AD progression by reducing
translocation of pro-inflammatory gut bacteria from gut to brain
and consequently neuroinflammation processes mediated by
them. However, most animal studies only examined the effects of
FMT with feces from AD patients or feces from animal models
of AD in healthy mice and not the opposite. The effects of
FMT in animal models of stroke are less clear. Performing FMT
in patients with high-risk for stroke may potentially decrease
infarct size when they develop stroke by a decrease of pro-
inflammatory immune cells trafficking to the infarct area. When
this mechanism is confirmed by future studies, this suggests that
FMT performed immediately after a stroke may also potentially
improve infarct size, but no studies have assessed this yet.
Interestingly, one mouse study (Winek et al., 2016) reported
an increased mortality rate, but similar infarct volume, after
FMT. The increased mortality may have been linked to increased
infarct size due to FMT, since infarct size was only measured
on day 1 after stroke-induction, but it could also be linked
to the antibiotic treatment. Remarkably, contrasting effects of
microbiota depletion by antibiotics were observed for stroke and
AD. The experimental results on FMT for epilepsy are even more
difficult to interpret, considering that there are several different
subtypes of epilepsy with different pathophysiology. Some, but
very limited evidence is available that suggests a potential role of
the gut microbiota in seizure susceptibility. Animal studies may
imply that the gut microbiota mediates a stress-induced increase
and ketogenic diet-induced decrease in seizure susceptibility. For
other neurological disorders, such as TS, diabetic neuropathy
and Guillain-Barré, the available evidence is very limited. For
these disorders and for epilepsy, animal studies need to be
replicated and expanded in future studies before an attempt
in humans.
Numerous trials on FMT in neurological disorders are
currently planned or ongoing and it is expected that the bulk
of evidence on the efficacy of FMT in neurological disorders
will grow.
For many disorders, research to date has been limited to
animal models. It should be noticed that in this field, as in
other fields, it is often not known whether results obtained
in animal studies are directly applicable to human patients.
Robustness of quality and mechanistic depth of animal models
differ widely for neurological disorders. Furthermore, behavior
and cognition tests in animal models may be subjective or
difficult to interpret and not reproducible. Another important
consideration is that the immunoreactivity of animal models
could be very different from that observed in patients. In some
animal studies, feces from humans were transferred to animal
models. This may not provide a good model for diseased or
healthy humans, considering the differences in gut microbiota
and subsequent host-microbiota interactions between humans
and animals (Hugenholtz and de Vos, 2018). For this reason,
assessment of gut microbiota composition in animal models of
disease may also not be reliable. Coprophagy, behavior that is



























TABLE 9 | FMT in Guillain-Barré syndrome.
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frequently observed in mice (Ebino et al., 1987), may also affect
the results of gutmicrobiota analyses and efficacy of FMT. Several
studies attempted to avoid this by caging mice separately, but
autologous FMT by coprophagy may still occur. This must all
be appraised, when translating findings in animal models into
human neurological disorders.
There are also other important limitations on both the human
and animal studies with FMT. These limitations are related to
the, often complex, study design, including for example the use
of different antibiotics, different FMT procedures, the choice
of different donors, and the lack of long term follow-up or
appropriate control groups.
For human studies, neuropsychiatric diseases analyzed with
subjective outcome measures are prone to strong placebo effects
after such an invasive treatment (Belcher et al., 2018). A
double-blinded design including a control group (for example
with autologous FMT) is desirable. Moreover, it is important
to acknowledge the possibility of publication bias, especially
regarding case reports. Case descriptions and studies with little
or no effect of FMT on disease symptoms or characteristics
were rare. In addition, several neurological disorders tend to
fluctuate in disease severity, which implicates that assessment
of FMT efficacy might be difficult. The mechanism of action
of FMT might be different in different disorders: while in
its consolidated use for recurrent C. difficile infections usually
a single FMT is sufficient to produce sustained benefit, for
neurological disorders, which are progressive in nature, multiple
FMT may be necessary to achieve a sustained response;
the required number of FMTs and effective interval between
multiple FMTs would then need to be evaluated. For a
few case descriptions and studies on ASD and PD, indeed
only transient positive effects were observed, but this may
also be explained by a placebo effect or fluctuations in
disease severity.
For some neurological disorders examined in this review,
contrasting evidence was observed in gut microbiota analysis
results. Various non-standardized methods could be used for the
assessment of the gut microbiota composition. The results of
microbiota analyses can be affected by a wide variety of factors
throughout the entire workflow of a microbiota study, starting
with sample collection and DNA extraction and ending with
choice of statistical tests. In addition, due to the influence ofmany
other patient- or subject related factors, including medication
use, diet, or age, inconsistency in gut microbiota composition
and α- and β-diversity analyses is often observed. Furthermore,
functional analyses of the gut microbiome, using metagenomics
and metabolomics, are emerging and may be more important
than the detection of taxa, exclusively reported by many studies.
What the gut bacteria produce and the concomitant effects on
processes in the human body is more important information than
which bacteria are present.
The safety of this experimental treatment should also be
better elucidated. Potential benefits of FMT should be carefully
weighed against the potential risks, and future studies should
focus primarily on safety, with effectivity of FMT as a secondary
endpoint. Indeed, not all human and animal studies mentioned
assessment of adverse events in subjects undergoing FMT
and potential long-term negative effects were rarely examined.
Side effects could be related to the administration route (e.g.,
gastroscopy or colonoscopy) (Wang et al., 2016), to the required
pretreatment (antibiotics and bowel lavage), or even to the
administration of feces itself, which could theoretically influence
the pathogenesis of the disorder in a negative way. Transferring
certain taxa or inducing an increase in α-diversity may turn
out to be beneficial or detrimental, and this may differ between
individual disorders. Whether all healthy donors or only a
few donors with certain gut microbiome characteristics are
suitable, is unknown. Rational feces donor selection, based
on available literature, may be crucial, but more knowledge
on the pathophysiology of several neurological disorders and
the relevant characteristics of the microbiome is required.
Also, future studies should answer the question whether
gut microbiota baseline profiles can predict who will benefit
from FMT. Herein, the use of appropriate methods for the
(preparation of) microbiota analysis and assessment of possible
confounding factors are crucial. Confounding factors should be
corrected for or prevented. Concomitantly, functional analyses
of the gut microbiome will have a crucial role in determining
which taxa are important in each neurological disorder. Also
important is that more evidence has to become available on
the number of FMTs required for each neurological disorder.
Furthermore, it is unclear whether pre-treatment with antibiotics
and bowel lavage is necessary in neurological disorders. The
current view in C. difficile infections is that pre-treatment
improves donor feces engraftment. In our opinion, a similar
pre-treatment as in C. difficile infections may also be required
to foster the effects of FMT in neurological disorders. In
the future, capsules that contain beneficial bacterial consortia
may replace FMT, thus increasing the comfort for patients
and reducing the potential side effects associated with the
administration route.
In conclusion, although some evidence is available, well-
designed large double-blinded randomized controlled trials in
human patients are needed to further elucidate the effect of FMT
in neurological disorders.
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